A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction (CHIARA MIA 2)

Bayer

Status and phase

Completed

Phase 2

Conditions

Myocardial Infarction

Treatments

Drug: Placebo

Drug: Fulacimstat (BAY1142524)

Study type

Interventional

Funder types

Industry

Identifiers

NCT02976467

2016-002167-33 (EudraCT Number)

16673

Details and patient eligibility

About

The purpose of the trial is the analysis of safety and efficacy of the chymase inhibitor BAY1142524 at a dose of 25 mg BID in comparison to placebo using a 6 months treatment period in patients with left-ventricular (LV) dysfunction after myocardial infarction (MI). BAY1142524 or placebo will be given on top of evidence-based standard of care for left-ventricular dysfunction after myocardial infarction. Primary objective is the analysis of first signs of efficacy as determined by favourable changes in functional parameters of adverse cardiac remodelling (i.e. endsystolic and enddiastolic volume index, ejection fraction). Secondary objective is the analysis of safety and tolerability as evidenced by the incidence and severity of adverse events. 30 patients have to complete treatment with verum and 30 patients have to complete treatment with placebo.

Enrollment

107 patients

Sex

All

Ages

40 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with first ST elevation myocardial infarction (STEMI) treated with primary percutaneous intervention (PCI) or thrombolysis within 24 hours after symptom onset
Diagnosis of STEMI requires the presence of the following three criteria:
- Typical clinical symptoms such as chest pain, shortness of breath for more than 20 minutes related to the myocardial infarction
- New ST elevation indicating myocardial infarction
- Significant elevation in troponin T or I with at least one value above the 99th percentile upper reference limit (URL) and/or elevation creatine kinase (CK) and creatine kinase MB (6-10% of total CK)
At the screening period, on day 5 to 9 after MI, patients have to have a LVEF ≤ 45% and an infarct size >10% LV mass (as measured by LGE-MRI, central-blinded evaluation)

Exclusion criteria

Contraindication to perform contrast-enhanced cardiac MRI
LVEF < 20%
History of heart failure or LVEF < 50% before occurrence of the first STEMI
Infarct size > 45% (g/g; LV mass) between 5 and 9 days after myocardial infarction
NYHA (New York Heart Association) class IV at randomization
Any planned cardiac intervention after baseline MRI or any other planned operations
Non-ischemic causes for cardiomyopathy
Diagnosis of atrial fibrillation
Systolic blood pressure < 100 mm Hg or > 180 mm Hg; diastolic blood pressure < 50 mm Hg or >110 mm Hg, heart rate < 50 or >100 beat/minute; mean of triplicate values at randomization
Clinically relevant hepatic dysfunction